← Browse by Condition
Medical Condition

lymphoma

Total Trials
23
Recruiting Now
23
Trial Phases
Phase 2, Phase 1, Phase 2, EARLY_Phase 1

Lymphoma trials span diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, Hodgkin lymphoma, mantle cell lymphoma, and T-cell lymphomas β€” each with distinct biology and treatment response. CAR-T cell therapy has established a new standard in relapsed/refractory DLBCL, and trials now aim to move this approach earlier in the treatment sequence.

Active trials evaluate bispecific antibodies (mosunetuzumab, epcoritamab, glofitamab), next-generation CAR-T cell products (CD19/CD22 dual targets, BCMA-targeting), BTK inhibitors in B-cell lymphomas, and total metabolic volume on PET as a predictive biomarker for treatment adaptation.

Frequently Asked Questions — lymphoma Clinical Trials

How many clinical trials are currently recruiting for lymphoma?
ClinicalMetric currently tracks 23 actively recruiting clinical trials for lymphoma, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 23. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for lymphoma?
lymphoma research spans Phase 1 (3 trials), Phase 2 (6 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a lymphoma clinical trial?
Eligibility criteria for lymphoma trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1
3
Phase 2
6
Top Sponsors
University Health Network, Toronto 2 trials
Memorial Sloan Kettering Cancer Center 2 trials
M.D. Anderson Cancer Center 2 trials
Henan Cancer Hospital 1 trial
University of Michigan Rogel Cancer Center 1 trial

Recruiting Clinical Trials

NCT04263935
Recruiting
Correlation Between Driver Gene Abnormalities and Clinicopathological Characteristics and Disease Prognosis in Lymphoma
Enrollment
200 pts
Location
China
Sponsor
Henan Cancer Hospital
View Trial →
NCT06047626
Recruiting
Living Well With Lymphoma
Enrollment
100 pts
Location
United States
Sponsor
University of Michigan Rogel C...
View Trial →
NCT02595255
Recruiting
AMH as a Predictor of Infertility Risk in Children With Cancer (CHANCE)
Enrollment
275 pts
Location
Belgium, France
Sponsor
Erasme University Hospital
View Trial →
NCT07032103
Recruiting
Prospective Cohort Study for Lymphoma: Samsung Lymphoma Cohort Study IV
Enrollment
2,000 pts
Location
South Korea
Sponsor
Samsung Medical Center
View Trial →
NCT05961410 Phase 2
Recruiting
Eltrombopag for Peripheral Blood Stem Cell Harvest
Enrollment
46 pts
Location
Taiwan
Sponsor
National Taiwan University Hos...
View Trial →
NCT07763054
Recruiting
Low-dose Liposomal Amphotericin B for Antifungal Prophylaxis in Prolonged Neutropenia Patients
Enrollment
30 pts
Location
China
Sponsor
Haikou Affiliated Hospital of ...
View Trial →
NCT07249905 Phase 1, Phase 2
Recruiting
Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma
Enrollment
180 pts
Location
Australia
Sponsor
ModeX Therapeutics, An OPKO He...
View Trial →
NCT05403177
Recruiting
Marathon of Hope Cancer Centres Network Study for Ontario (MOHCCN-O)
Enrollment
500 pts
Location
Canada
Sponsor
University Health Network, Tor...
View Trial →
NCT00582621
Recruiting
Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders
Enrollment
500 pts
Location
United States
Sponsor
Memorial Sloan Kettering Cance...
View Trial →
NCT07553572
Recruiting
Remote Monitoring and Symptom Management Digital Application
Enrollment
60 pts
Location
United States
Sponsor
Patrick C. Johnson, MD
View Trial →
NCT05745285
Recruiting
Leukemia and Lymphoma Society (LLS) Services Impact on Outcomes and Care
Enrollment
400 pts
Location
United States
Sponsor
University of Miami
View Trial →
NCT06343311 Phase 1, Phase 2
Recruiting
T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)
Enrollment
21 pts
Location
United States
Sponsor
Estrella Biopharma, Inc.
View Trial →
NCT05982223
Recruiting
Integrative Medicine in Lymphoma Survivors
Enrollment
90 pts
Location
Israel
Sponsor
Bnai Zion Medical Center
View Trial →
NCT06471296
Recruiting
Virus-associated Tumour Microenvironment
Enrollment
150 pts
Location
France
Sponsor
Assistance Publique - Hôpitaux...
View Trial →
NCT06193369
Recruiting
Digital Peer Navigation for Adolescents and Young Adults With Cancer
Enrollment
138 pts
Location
Canada
Sponsor
University Health Network, Tor...
View Trial →
NCT06854003 Phase 2
Recruiting
BRAZAN: A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance in Treatment-Naïve Mantle Cell Lymphoma
Enrollment
60 pts
Location
United States
Sponsor
Christine Ryan
View Trial →
NCT05294367 EARLY_Phase 1
Recruiting
Dietary and Topical Magnesium Replacement or Supplementation in Patients With Lymphoma
Enrollment
60 pts
Location
United States
Sponsor
Mayo Clinic
View Trial →
NCT05929612 Phase 2
Recruiting
A Study of Response Adapted Ultra Low Dose 4 Gy Radiation for Definitive Therapy of Marginal Zone Lymphoma
Enrollment
50 pts
Location
United States
Sponsor
M.D. Anderson Cancer Center
View Trial →
NCT02974647 Phase 2
Recruiting
Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma
Enrollment
83 pts
Location
United States
Sponsor
Memorial Sloan Kettering Cance...
View Trial →
NCT07226934
Recruiting
An AI-Generated, Personalized Question Prompt List Intervention for Patients With Hematologic Cancers
Enrollment
40 pts
Location
United States
Sponsor
Washington University School o...
View Trial →
NCT06203652
Recruiting
The Pathogenesis and Prognostic Factors of Lymphoma
Enrollment
2,000 pts
Location
China
Sponsor
Shanghai Zhongshan Hospital
View Trial →
NCT05011045
Recruiting
Neurocognitive Outcomes After Whole Brain Radiation Therapy for Hematologic Malignancies
Enrollment
100 pts
Location
United States
Sponsor
M.D. Anderson Cancer Center
View Trial →
NCT06774326
Recruiting
Role of Spectral CT in the Evaluation of Cardiotoxicity in Patients With Hodgkin's Lymphoma and Diffuse Large B-cell Lymphoma Treated With Anthracyclines
Enrollment
160 pts
Location
Italy
Sponsor
IRCCS Azienda Ospedaliero-Univ...
View Trial →

Related Conditions

leukemia (4) multiple myeloma (3) breast cancer (2) colorectal cancer (2) non hodgkin lymphoma (2) gene abnormality (1) fertility preservation (1) pediatrics cancer (1) gonadotropin releasing hormone agonist (1) peripheral blood stem cell transplantation (1) acute myeloid leukemia (1) acute lymphoblastic leukemia (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology